Formulations, liquid parenteral/injectable

The liquid formulation for parenteral administration requires additional physical and microbiological functionalities, such as syringeability, sterility, osmolarity, and pyrogen freedom. The particle size change can influence the syringeability of injection of a suspension formulation as well as the level of irritation at the site. Terminal sterilization such as autoclave or gamma irradiation may affect the physical stability of the dosage form. Both formulation and container systems should be evaluated [63]. 

Protein-based drugs have been formulated mainly as stable liquids or in cases where liquid stability is limiting as lyophilized dosage forms to be reconstituted with a suitable diluent prior to injection. This is because their delivery has been limited primarily to the parenteral routes of intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration. There are a few drugs that have been developed for pulmonary delivery, such as rhDNase (Pulmozyme ) and an inhalable formulation of insulin (e.g., Exubra ). However, even such drugs have been formulated as either liquid or lyophilized or spray-dried powders. This chapter will focus only on excipients that are applicable to liquid and lyophilized protein formulations. 

Since the administration routes are mainly parenteral, the formulation has to be injectable. An injectable formulation requires specific excipients, ways of preparation and formulation types liquid, suspension, or solid formulations. In the development of protein drugs, various formulation principles are used. In Table 5, examples of some of the formulation principles are given. 

Liquid formulations should be prepared in an area that Is as clean as possible. Water for parenteral products should be of pharmacopoeial Water for Injection quality. Mixing vessels and other equipment should be cleaned and disinfected. It is normal for these areas to be provided with filtered air from HEPA fllteis of somewhat lower efficiencies than those providing protection to aseptic filling rooms. Sterilization of liquid products should be by filtration through... 

Apart from the already established formulations, researchers are trying to develop novel oil-based formulations to combat the poor solubility and bioavailablity of NCE. Shevachman et al. developed novel U-type microemulsions to improve the percutaneous permeability of diclofenac. Shah et al.2 2 used microwave heating for the preparation of solid lipid nanoparticles by microemulsion techniques, which resulted in improved particle characteristics. Ki et al. reported sustained-release liquid crystal of injectable leuprolide using sorbitan monooleate. Recently, various novel oil-based drug delivery technologies are reported, which includes tocol emulsions, solid lipid nanopar-ticles, nanosuspensions, Upid microbubbles, sterically stabilized phospholipid micelles, and environmentally responsive drug delivery systems for parenteral administration.25 259... 

---